StockData
Alaunos Therapeutics, Inc. logo

Alaunos Therapeutics, Inc. (TCRT) stock

TCRTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 4/30
$1.66+0.06 (+3.75%)

Close on Nov 17, 2026Market cap $4.22MP/E –Yield –

Alaunos Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Alaunos Therapeutics's ebitda for the twelve months ending Sep 30, 2017 was -$50.85M. For fiscal 2016 it was -$165.02M. The highest annual figure on record is -$11.79M in fiscal 2009.

Annual ebitda

PeriodPeriod endValueChange
FY2016Dec 31, 2016-$165.02M–
FY2015Dec 31, 2015-$119.74M–
FY2014Dec 31, 2014-$43.04M–
FY2013Dec 31, 2013-$56.98M–
FY2012Dec 31, 2012-$101.51M–
FY2011Dec 31, 2011-$71.13M–
FY2010Dec 31, 2010-$24.36M–
FY2009Dec 31, 2009-$11.79M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2018Sep 30, 2018-$12.41M–
Q2 FY2018Jun 30, 2018-$12.24M–
Q1 FY2018Mar 31, 2018-$16.08M–
Q3 FY2017Sep 30, 2017-$12.99M–
Q2 FY2017Jun 30, 2017-$12.93M–
Q1 FY2017Mar 31, 2017-$13.89M–
Q4 FY2016Dec 31, 2016-$11.05M–
Q3 FY2016Sep 30, 2016-$10.84M–
Q2 FY2016Jun 30, 2016-$131.16M–

More Alaunos Therapeutics figures

See a number that looks wrong?